BioCentury
ARTICLE | Politics & Policy

WHO: Congo may approve mAb Zmapp for Ebola outbreak

May 18, 2018 11:03 PM UTC

The Democratic Republic of the Congo is likely to approve the use of Zmapp “in the coming days” to treat patients affected by the country's Ebola outbreak, the World Health Organization said Friday.

President Larry Zeitlin told BioCentury that Mapp Biopharmaceutical Inc. (San Diego, Calif.) has a stockpile of emergency use doses of Zmapp and will be "very willing" to provide the product to the country. He declined to disclose how many doses are in the stockpile. Zmapp, which comprises three mAbs targeting Ebola glycoproteins GP1 and GP2, is in the Phase I/II PREVAIL II trial...